Implications of Vitamin D in Multiple Sclerosis and Other Neurodegenerative Processes: Bibliometric Analysis and Systematic Review

2019 ◽  
Vol 18 (6) ◽  
pp. 478-490 ◽  
Author(s):  
Javier Caballero-Villarraso ◽  
María J. Jiménez-Jiménez ◽  
Begoña M. Escribano ◽  
Eduardo Agüera ◽  
Abel Santamaría ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Vitamin D ◽  
Neurodegenerative Diseases ◽  
Bibliometric Analysis ◽  
Scientific Evidence ◽  
Future Trend ◽  
Clinical Severity ◽  
Double Blind ◽  
Parkinson’S Diseases

: In recent years, numerous investigations focused on the pleiotropic actions of vitamin D have been carried out. These actions include the participation of this molecule in neurophysiological and neuropathological processes. As a consequence, abundant scientific literature on the role of this vitamin in neurodegenerative entities has emerged, even concerning clinical studies. To identify the level of scientific evidence concerning the relation between vitamin D and neurodegenerative diseases, from a quantitative and qualitative perspective. To describe, by means of a bibliometric analysis, the scientific production and its evolution through time in quantitative terms, regarding the implications of vitamin D in neurodegeneration. To analyse and present the degree of evidence in the aforementioned field of study, a systematic review of the literature focused on the most prevalent neurodegenerative diseases was carried out. We retrieved 848 articles in the bibliometric analysis, the majority of which were dated between the years 2010-2017. The most studied metabolite was the 25(OH)D3 and the most cited disease was multiple sclerosis. In the systematic review, we found studies about Alzheimer’s and Parkinson’s diseases and again, about multiple sclerosis prominently (in number and quality), with 12 randomised double-blind clinical trials. The research about vitamin D and its relations with neurodegenerative diseases shows a growing evolution over the last decade. More studies are needed to find correlations between the clinical severity of these diseases and the specific status of vitamin D and the genotypes related with them, which seems to be a future trend.

scholarly journals A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Trials Examining the Clinical Efficacy of Vitamin D in Multiple Sclerosis

2013 ◽  
Vol 40 (3) ◽  
pp. 147-153 ◽  
Author(s):  
Beatriz Pozuelo-Moyano ◽  
Julián Benito-León ◽  
Alex J. Mitchell ◽  
Jesús Hernández-Gallego
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Vitamin D ◽  
Clinical Efficacy ◽  
Controlled Trials ◽  
Double Blind ◽  
Double Blind Placebo

Gene and cell therapy and nanomedicine for the treatment of multiple sclerosis: bibliometric analysis and systematic review of clinical outcomes

2021 ◽  
pp. 1-11
Author(s):  
Javier Caballero-Villarraso ◽  
Jamil Sawas ◽  
Begoña M. Escribano ◽  
Francisco A. Martín-Hersog ◽  
Andrea Valverde-Martínez ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Cell Therapy ◽  
Clinical Outcomes ◽  
Bibliometric Analysis ◽  
Gene And Cell Therapy

scholarly journals Supplementation and therapeutic use of vitamin D in patients with multiple sclerosis: Consensus of the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology

2014 ◽  
Vol 72 (2) ◽  
pp. 152-156 ◽  
Author(s):  
Doralina Guimarães Brum ◽  
Elizabeth Regina Comini-Frota ◽  
Claúdia Cristina F. Vasconcelos ◽  
Elza Dias-Tosta
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Vitamin D ◽  
Environmental Factors ◽  
Scientific Evidence ◽  
Hypovitaminosis D ◽  
Central Nervous System Disease ◽  
Keywords Multiple Sclerosis ◽  
System Disease ◽  
Genetic And Environmental Factors

Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating, and degenerative central nervous system disease. Even though the etiology of MS has not yet been fully elucidated, there is evidence that genetic and environmental factors interact to cause the disease. Among the main environmental factors studied, those more likely associated with MS include certain viruses, smoking, and hypovitaminosis D. This review aimed to determine whether there is evidence to recommend the use of vitamin D as monotherapy or as adjunct therapy in patients with MS. We searched PUBMED, EMBASE, COCHRANNE, and LILACS databases for studies published until September 9 th , 2013, using the keywords “multiple sclerosis”, “vitamin D”, and “clinical trial”. There is no scientific evidence up to the production of this consensus for the use of vitamin D as monotherapy for MS in clinical practice.

scholarly journals Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis

2021 ◽  
Vol 8 (2) ◽  
pp. 239-253
Author(s):  
Mahmood Moosazadeh ◽  
◽  
Fatemeh Nabinezhad-Male ◽  
Mahdi Afshari ◽  
Mohammad Mehdi Nasehi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Vitamin D ◽  
Meta Analysis ◽  
Vitamin D Status

scholarly journals Immune Responses in Neurodegenerative Diseases

2015 ◽  
Vol 12 (1) ◽  
pp. 67-76 ◽  
Author(s):  
R Shrestha ◽  
Shakya Shrestha ◽  
O Millington ◽  
J Brewer ◽  
T Bushell
Keyword(s):  
Multiple Sclerosis ◽  
Immune Responses ◽  
Neurodegenerative Diseases ◽  
Immune Cells ◽  
Review Article ◽  
Progressive Loss ◽  
Parkinson’S Diseases ◽  
Key Factor ◽  
Huge Impact ◽  
Diseased Condition

Neurodegenerative disease is a progressive loss of neurons from central nervous system and has a huge impact on health care system. Various causes have been proposed of which inflammation has been suggested to be a probable key factor in the most of such conditions. The involvement of immune cells including lymphocytes in such diseased condition of the CNS supports this notion. The effective therapy for these diseases has been sought for more than a half century but still lacking such therapy. On such basis this review article has mainly focussed on evidence of the involvement of immune cells in various neurodegenerative diseases including Alzheimer’s disease, Parkinson’s diseases and Multiple sclerosis and suggests a possible therapy of such diseased conditions of the CNS by the modulation of immune system.Kathmandu University Medical Journal Vol.12(1) 2014: 67-76

scholarly journals Geospatial Analysis of Environmental Atmospheric Risk Factors in Neurodegenerative Diseases: A Systematic Review

2020 ◽  
Vol 17 (22) ◽  
pp. 8414
Author(s):  
Mariana Oliveira ◽  
André Padrão ◽  
André Ramalho ◽  
Mariana Lobo ◽  
Ana Cláudia Teodoro ◽  
...  
Keyword(s):  
Risk Factors ◽  
Multiple Sclerosis ◽  
Systematic Review ◽  
Neurodegenerative Diseases ◽  
Nitrogen Dioxide ◽  
Neurodegenerative Disease ◽  
Environmental Influence ◽  
Sun Exposure ◽  
Geospatial Analysis ◽  
Atmospheric Factors

Despite the vast evidence on the environmental influence in neurodegenerative diseases, those considering a geospatial approach are scarce. We conducted a systematic review to identify studies concerning environmental atmospheric risk factors for neurodegenerative diseases that have used geospatial analysis/tools. PubMed, Web of Science, and Scopus were searched for all scientific studies that included a neurodegenerative disease, an environmental atmospheric factor, and a geographical analysis. Of the 34 included papers, approximately 60% were related to multiple sclerosis (MS), hence being the most studied neurodegenerative disease in the context of this study. Sun exposure (n = 13) followed by the most common exhaustion gases (n = 10 for nitrogen dioxide (NO2) and n = 5 for carbon monoxide (CO)) were the most studied atmospheric factors. Only one study used a geospatial interpolation model, although 13 studies used remote sensing data to compute atmospheric factors. In 20% of papers, we found an inverse correlation between sun exposure and multiple sclerosis. No consensus was reached in the analysis of nitrogen dioxide and Parkinson’s disease, but it was related to dementia and amyotrophic lateral sclerosis. This systematic review (number CRD42020196188 in PROSPERO’s database) provides an insight into the available evidence regarding the geospatial influence of environmental factors on neurodegenerative diseases.

The Influence of Vitamin D on Neurodegeneration and Neurological Disorders: A Rationale for its Physio-pathological Actions

2020 ◽  
Vol 26 (21) ◽  
pp. 2475-2491 ◽  
Author(s):  
Maria Morello ◽  
Massimo Pieri ◽  
Rossella Zenobi ◽  
Alessandra Talamo ◽  
Delphine Stephan ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Neurodegenerative Diseases ◽  
Neurological Disorders ◽  
Neurological Diseases ◽  
Steroid Hormone ◽  
Neuroactive Steroid ◽  
Brain Functions ◽  
Prevention And Treatment ◽  
Lateral Sclerosis

Vitamin D is a steroid hormone implicated in the regulation of neuronal integrity and many brain functions. Its influence, as a nutrient and a hormone, on the physiopathology of the most common neurodegenerative diseases is continuously emphasized by new studies. This review addresses what is currently known about the action of vitamin D on the nervous system and neurodegenerative diseases such as Multiple Sclerosis, Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis. Further vitamin D research is necessary to understand how the action of this “neuroactive” steroid can help to optimize the prevention and treatment of several neurological diseases.

scholarly journals A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis

2017 ◽  
Vol 26 (9) ◽  
pp. 1560-1571 ◽  
Author(s):  
Dong Seok Kim ◽  
Ho-Il Choi ◽  
Yun Wang ◽  
Yu Luo ◽  
Barry J. Hoffer ◽  
...  
Keyword(s):  
Risk Factor ◽  
Neurodegenerative Diseases ◽  
Physiological Role ◽  
Open Label ◽  
Effective Treatment Option ◽  
Neuroprotective Effects ◽  
Double Blind ◽  
Parkinson’S Diseases ◽  
Dipeptidyl Peptidase 4 Inhibitors

Molecular communications in the gut–brain axis, between the central nervous system and the gastrointestinal tract, are critical for maintaining healthy brain function, particularly in aging. Epidemiological analyses indicate type 2 diabetes mellitus (T2DM) is a risk factor for neurodegenerative disorders including Alzheimer's disease (AD) and Parkinson's diseases (PD) for which aging shows a major correlative association. Common pathophysiological features exist between T2DM, AD, and PD, including oxidative stress, inflammation, insulin resistance, abnormal protein processing, and cognitive decline, and suggest that effective drugs for T2DM that positively impact the gut–brain axis could provide an effective treatment option for neurodegenerative diseases. Glucagon-like peptide-1 (GLP-1)-based antidiabetic drugs have drawn particular attention as an effectual new strategy to not only regulate blood glucose but also decrease body weight by reducing appetite, which implies that GLP-1 could affect the gut–brain axis in normal and pathological conditions. The neurotrophic and neuroprotective effects of GLP-1 receptor (R) stimulation have been characterized in numerous in vitro and in vivo preclinical studies using GLP-1R agonists and dipeptidyl peptidase-4 inhibitors. Recently, the first open label clinical study of exenatide, a long-acting GLP-1 agonist, in the treatment of PD showed long-lasting improvements in motor and cognitive function. Several double-blind clinical trials of GLP-1R agonists including exenatide in PD and other neurodegenerative diseases are already underway or are about to be initiated. Herein, we review the physiological role of the GLP-1R pathway in the gut–brain axis and the therapeutic strategy of GLP-1R stimulation for the treatment of neurodegenerative diseases focused on PD, for which age is the major risk factor.

Sign in / Sign up

Export Citation Format

Share Document